Pazopanib (Teva) 200 mg tablets: Supply issue

Supply issue Section 29A Active

Due to manufacturing changes, there is limited stock of the 200 mg strength of pazopanib tablets (Pharmacode: 2695332).

Affected product

Teva, the supplier, will run out of the following product:

  • Chemical: Pazopanib
  • Presentation: Tab 200 mg
  • Brand: Pazopanib Teva
  • Pharmacode: 2695332
  • Subsidy: $172.88
  • Measure / Qty: per 30

The 400 mg is not affected by this supply issue.

Schedule listing for pazopanib(external link)

Alternative funded from 1 April

The following product will be funded in the Schedule from 1 April. It is not Medsafe approved and will need to be prescribed and dispensed in line with section 29A of the Medicines Act.

  • Chemical: Pazopanib
  • Presentation: Tab 200 mg
  • Brand: Pazopanib ADVZ
  • Pharmacode: 2726645
  • Subsidy: $172.88
  • Measure / Qty: per 30

Section 29 and OP apply.

This was an out-of-cycle listing. It will appear in dispensing software as normal. It will be visible in the Online Schedule in due course. Pharmacists will be able to claim as normal. 

Expected resupply

We are working with Teva to understand when Pazopanib Teva 200 mg tablets will be available again.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

Sign up to our email list for regular emails about supply issues and more(external link)